Bayer (BAYRY) Cut to “Sell” at Zacks Investment Research
Bayer (OTCMKTS:BAYRY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.
According to Zacks, “Bayer’s earnings beat estimates and revenues declined year over year in the fourth quarter of 2017. During the fourth quarter of 2017, the Crop Science business reported declined mainly due to the situation in the Brazilian crop protection business. The company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Bayer’s dependence on its pharmaceutical segment for growth remains a concern. Bayer’s shares have underperformed the industry in the past one year.However, as part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell its entire Crop Science businesses to BASF. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions.”
Separately, ValuEngine cut shares of Bayer from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd.
Bayer (OTCMKTS:BAYRY) last issued its earnings results on Wednesday, February 28th. The company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.11. The business had revenue of $10.12 billion for the quarter. Bayer had a net margin of 10.84% and a return on equity of 22.39%. sell-side analysts anticipate that Bayer will post 2.38 earnings per share for the current fiscal year.
Bayer Company Profile
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.